KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
2009 · British Journal of Cancer · 557 citations
https://doi.org/10.1038/sj.bjc.6605177
A
Annamaria Ruzzo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
117
Papers
4.6K
Citations
32
h-index
56
i10-index
Annamaria Ruzzo is an academic researcher from University of Urbino. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Gastric Cancer Management and Outcomes & Genetic factors in colorectal cancer. The author has an h-index of 32, co-authored 100 publications.
Papers by this author
worksRetrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
2011 · BMC Cancer · 74 citations
https://doi.org/10.1186/1471-2407-11-247
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
2008 · British Journal of Cancer · 30 citations
https://doi.org/10.1038/sj.bjc.6604555
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC)
2016 · Scientific Reports · 24 citations
https://doi.org/10.1038/srep34006
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
2020 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-020-58486-6
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
2010 · British Journal of Cancer · 0 citations
https://doi.org/10.1038/sj.bjc.6605583
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat